

Clinical Compendium:

A Critical Update on Therapy Selection, Sequencing, and Toxicity Management of Novel Therapies for Multiple Myeloma



Key Concepts

Dear Colleague:

Thank you for your recent participation in the CE activity *A Critical Update on Therapy Selection, Sequencing, and Toxicity Management of Novel Therapies for Multiple Myeloma*, with Sagar Lonial, MD, developed by the Annenberg Center for Health Sciences. As you continue to advance the care you provide to these patients, here are the key concepts for you to consider:

- Disease staging and cytogenetics are important aspects to consider when determining risk stratification and front-line treatment selection for patients with newly diagnosed multiple myeloma.
- Choosing the optimal induction therapy likely has a significant impact on long-term outcomes. Most recent trials suggest the addition of daratumumab to standard triplet IMiD/PI induction deepens the response and increases the fraction of MRD-negative patients earlier on.
- Patients with triple-class refractory disease have poor outcomes, necessitating development of novel agents with novel targets. Currently, these include CAR T-cell therapy, bispecific antibodies, selinexor, and venetoclax.
- Clinicians should implement effective strategies in order to prevent treatment-related toxicity so that treatment can be maintained.

We hope you will be able to participate in other accredited activities we offer. You will find information at www.Annenberg.net.

Regards,
The Annenberg Center Team